Source-grounded facts extracted from Drugs Made In America Acquisition II Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Drugs Made In America Acquisition II Corp. entered into Interim Convertible Note with Alpha Multi Family Office valued at $300,000 Interim Convertible Note, convertible with 35% discount (effective 2026-03-30).
“on March 30, 2026, the Company and the Investor entered into an Interim Convertible Note in the amount of $300,000 (the " Second Note ").”
Drugs Made In America Acquisition II Corp. entered into Definitive Investment and Sponsor Transition Agreement with Alpha Multi Family Office valued at $1,400,000 Convertible Notes Financing (effective 2026-03-24).
“Effective March 24, 2026, the Company and the Investor entered into the Definitive Investment and Sponsor Transition Agreement (the " Agreement ") for the Convertible Notes Financing, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.”
Drugs Made In America Acquisition II Corp. incurred convertible notes of $300,000 with Alpha Multi Family Office at does not bear interest maturing nine months from the date of issuance.
“In addition, on March 30, 2026, the Company and the Investor entered into an Interim Convertible Note in the amount of $300,000 (the “ Second Note ”).”
Drugs Made In America Acquisition II Corp. incurred convertible notes of $150,000 with Alpha Multi Family Office at does not bear interest maturing nine months from the date of issuance.
“On March 11, 2026, Drugs Made In America Acquisition II Corp. (the “ Company ”) issued an unsecured convertible note (the “ Bridge Note ”) to Alpha Multi Family Office (the “ Investor ”) in the principal amount of $150,000 (the “ Bridge Loan ”).”
Drugs Made In America Acquisition II Corp. entered into Bridge Note with Alpha Multi Family Office valued at $150,000 (effective 2026-03-11).
“On March 11, 2026, Drugs Made In America Acquisition II Corp. (the “ Company ”) issued an unsecured convertible note (the “ Bridge Note ”) to Alpha Multi Family Office (the “ Investor ”) in the principal amount of $150,000 (the “ Bridge Loan ”).”
Drugs Made In America Acquisition II Corp. issued 1,200,000 units of unit to the Sponsor and Cantor for $10.00 per Private Unit, generating total proceeds of $12,000,000.
“Simultaneously with the closing of the IPO, the Company consummated the private placement ("Private Placement") of an aggregate of 1,200,000 units (the "Private Units") to the Sponsor and Cantor, with 700,000 Private Units to the Sponsor and 500,000 Private Units to Cantor, at a price of $10.00 per Private Unit, generating total proceeds of $12,000,000.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.